menu
    • menu
    [{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Netarsudil Mesylate

    Menu

    Netarsudil Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clin...

                            Details : Netarsudil 0.02% is known by the name Rhokiinsa® in the European Union, where it is approved for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension.

                            Product Name : Roclanda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 12, 2021

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Soluti...

                            Details : The study was designed in accordance with the requirements of Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) to support a potential regulatory submission of netarsudil ophthalmic solution in Japan.

                            Product Name : Roclanda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2021

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclanda

                            Details : European Commission has granted a marketing authorisation for Roclanda® 0.02%/0.005% for high intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil are insufficie...

                            Product Name : Roclanda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union

                            Details : The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solu...

                            Product Name : Roclanda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 13, 2020

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical T...

                            Details : Aerie Pharmaceuticals successful interim 90-day topline data from its six-month Phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda® to Ganfort®.

                            Product Name : Roclanda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2020

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19

                            Details : Aerie expects to hold a meeting with the regulatory authorities in Japan during to discuss Phase 3 trial designs for Rhopressa® while continuing to explore partnership opportunities.

                            Product Name : Roclanda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2020

                            Lead Product(s) : Netarsudil Mesylate,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth